By Natalie Grover (Reuters) - Sarepta Therapeutics Inc suffered yet another setback after U.S. regulators asked for more data on its experimental muscle disorder drug, a move that further delays the marketing application for the treatment. Nearly a third of Sarepta's market value was wiped out on Monday after the company disclosed the U.S. Food and Drug Administration's decision on eteplirsen, its lead drug. ...
via Health News Headlines - Yahoo News
Read More Here.. 
Lake forest health and fitness http://ift.tt/1rNsjgr
No comments:
Post a Comment